Our Journey
2022
ELISA for bispecific antibody drugs
Launched the world's first range of ELISA for bispecific antibody drugs. Inaugurated our new ISO 13485 certified manufacturing facility in Bhiwandi, India.
2021
300+ new ELISA
Therapeutic Drug Monitoring ELISA range expanded to include 300+ new ELISA, along with several more assays for COVID-19 vaccine development. Broke ground for our new IVD production facility.
2020
Helped in COVID-19 research
Krishgen supports COVID-19 research by manufacturing a wide range of SARS-CoV-2 ELISA and well as develops one of the India’s first COVID-19 PCR tests for diagnostic use.
2019
New Achievement
Krishgen becomes the first in the world to commercialize assays for Insulin Analogs and GLP1 Agonists
2018
Krishgen expands manufacturing
Krishgen expands the biotherapeutics ELISA range, and opens the doors to a larger manufacturing lab.
2016
KRIBIOLISA Biotherapeutics ELISA launched
KRIBIOLISA Biotherapeutics ELISA launched, with Pharmacokinetic and Anti Drug Antibody ELISA
2015
International Distribution
International Distribution efforts started.
2013
Bonded Warehouse
Bonded Warehouse established to enable us to offer users in India customs duty benefits.
2011
GENLISA Gold Ring Cytokine ELISA
GENLISA Gold Ring Cytokine ELISA range added to manufacturing portfolio, competing with leading ELISA manufacturers from the US.
2007
GENLISA Gold Ring Cytokine ELISA
GENLISA Gold Ring Cytokine ELISA range added to manufacturing portfolio, competing with leading ELISA manufacturers from the US.
2005
2004
First partnership Research and life sciences products introduced through distribution arrangements with leading US and Europe companies.
2003
The beginning Krishgen Biosystems is launched as a distributor for international diagnostics companies in Mumbai, India by Neelam and Kalpesh Jain.